Ipamorelin: A Pentapeptide Ghrelin Receptor Agonist¶
Quick Facts¶
| Full Name | Ipamorelin (INN); NNC 26-0161 (developmental code) |
| Class | Synthetic pentapeptide ghrelin receptor agonist / Growth hormone secretagogue (GHS) |
| Amino Acid Sequence | Aib–His–d-2-Nal–d-Phe–Lys–NH₂ (modified pentapeptide) |
| Molecular Formula | C₃₈H₄₉N₉O₅ |
| Molecular Weight | ~711 Da |
| Target Receptor | Growth hormone secretagogue receptor 1a (GHS-R1a) |
| Mechanism | GHS-R1a agonist; stimulates pulsatile GH release with minimal effect on prolactin, ACTH, or cortisol |
| Selectivity Profile | Highly selective for GHS-R1a; no significant affinity for GHRH receptor or other pituitary targets |
| Route of Administration | Subcutaneous injection; intravenous (research use) |
| PubChem CID | 9939673 |
| CAS Number | 170851-47-7 |
Executive Summary¶
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that acts as a highly selective agonist of the ghrelin receptor (GHS-R1a, growth hormone secretagogue receptor type 1a). First described by Raun and colleagues at Novo Nordisk in 1998, ipamorelin was designed through a structure-activity optimization program building on the earlier hexapeptide GHRP-2 (pralmorelin), with the explicit goal of retaining full GH secretory potency while achieving an improved selectivity profile — specifically, minimizing off-target activation of the hypothalamic-pituitary-adrenal (HPA) axis.
Ipamorelin is distinguished from earlier growth hormone-releasing peptides (GHRPs) by its minimal stimulation of ACTH, cortisol, and prolactin release. This selectivity profile — GH release with negligible stress-axis activation — is the defining pharmacological feature of ipamorelin and the basis for its value as a research tool in endocrine physiology. Comparative studies have established that while hexarelin and GHRP-6 produce ACTH and cortisol elevations of 30–60% of the GH response magnitude, ipamorelin elicits less than 5% HPA axis activation at doses that produce robust GH pulsatility.
The molecular basis for ipamorelin's selectivity is increasingly understood through the framework of biased agonism at the GHS-R1a receptor. Computational docking and functional signaling studies suggest that ipamorelin's compact pentapeptide structure — incorporating the non-natural amino acids Aib (α-aminoisobutyric acid), d-2-Nal (D-3-(2-naphthyl)alanine), and d-Phe (D-phenylalanine) — occupies a distinct subset of the GHS-R1a binding pocket, stabilizing a receptor conformation that couples efficiently to Gq/11-mediated signaling while displaying reduced efficacy for β-arrestin recruitment and non-canonical pathways. This biased signaling at the receptor level provides a mechanistic explanation for the dissociation between GH secretagogue activity and stress-axis activation.
Ipamorelin has been evaluated in Phase I and Phase II clinical studies, including trials examining effects on body composition, bone metabolism, and GH deficiency states. It remains exclusively a research compound without FDA approval for any clinical indication. High-purity ipamorelin with comprehensive analytical documentation is available from RPL Peptide, with detailed characterization data at the RPL Peptide Data Center.
Background¶
Discovery and Development¶
The discovery of growth hormone secretagogues (GHSs) represents a convergence of serendipitous observation and systematic medicinal chemistry. In the late 1970s, Bowers and colleagues observed that certain synthetic met-enkephalin analogs — originally designed as opioid receptor ligands — could stimulate growth hormone release from the anterior pituitary. This activity was independent of the growth hormone-releasing hormone (GHRH) receptor, suggesting the existence of a previously unrecognized receptor system regulating GH secretion.
Through iterative optimization of the enkephalin scaffold, Bowers synthesized a series of GH-releasing peptides (GHRPs) — including GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) — that potently stimulated GH release both in vitro (from cultured pituitary somatotrophs) and in vivo (following intravenous or subcutaneous administration in humans) (Bowers, 1998). The GHRPs exhibited several distinctive features: they acted synergistically with GHRH to produce supra-physiological GH pulses, they were active across species, and they stimulated GH release through a receptor distinct from the GHRH receptor.
The molecular identity of the GHS receptor remained elusive until 1996, when Howard and colleagues at Merck Research Laboratories cloned and characterized GHS-R1a, a G protein-coupled receptor (GPCR) with high affinity for synthetic GHSs including MK-0677 and GHRP-6 (Howard et al., 1996). Remarkably, the endogenous ligand for this receptor remained unknown for an additional three years, until the landmark discovery of ghrelin — a 28-amino-acid acylated peptide hormone produced primarily by the X/A-like cells of the gastric fundus — by Kojima and colleagues in 1999 (Kojima et al., 1999). Ghrelin was shown to be the natural ligand for GHS-R1a, with its unique n-octanoyl modification at Ser³ essential for receptor activation.
Ipamorelin (NNC 26-0161) emerged from a medicinal chemistry program at Novo Nordisk that systematically explored truncated and modified analogs of GHRP-2 (Raun et al., 1998). The design goal was to reduce the pentapeptide to its minimal pharmacophore while eliminating cross-reactivity with receptors mediating ACTH release. The resulting molecule — incorporating three non-natural amino acids (Aib, d-2-Nal, d-Phe) and a C-terminal amide — represented a significant advance in GHS selectivity.
Research Context: The Somatotropic Axis¶
Ipamorelin's biological context is the somatotropic axis — the neuroendocrine system governing growth hormone secretion and action. The axis comprises: - Hypothalamic inputs: GHRH (stimulatory) and somatostatin (inhibitory), released from the arcuate and periventricular nuclei, respectively - Ghrelin/GHS-R1a system: An additional stimulatory pathway, with ghrelin produced peripherally (stomach) and centrally (hypothalamus) - Pituitary somatotrophs: GH-producing cells of the anterior pituitary that integrate hypothalamic and peripheral signals - Peripheral targets: GH receptors on liver, muscle, bone, and adipose tissue, mediating effects directly and through IGF-1
The GHS-R1a receptor is a Gq/11-coupled GPCR with exceptionally high constitutive (ligand-independent) activity — approximately 50% of maximal agonist-induced signaling — a property that distinguishes it from most other GPCRs and is thought to contribute to the tonic regulation of GH secretion (Holst et al., 2003).
Core Science¶
Mechanism of Action: GHS-R1a Agonism and Biased Signaling¶
Ipamorelin's primary mechanism of action is agonism at the GHS-R1a receptor (the ghrelin receptor), a Gq/11-coupled GPCR highly expressed in the hypothalamus (arcuate nucleus, ventromedial nucleus) and anterior pituitary, with significant expression also detected in the pancreas, gastrointestinal tract, adipose tissue, bone, and cardiovascular system.
Canonical Gq/11 Signaling Pathway¶
Ipamorelin binding to GHS-R1a activates the heterotrimeric G protein Gq/11, which in turn activates phospholipase C-β (PLC-β). PLC-β catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP₂) to generate two second messengers: - Inositol 1,4,5-trisphosphate (IP₃): Diffuses to the endoplasmic reticulum, where it binds to IP₃ receptors and triggers the release of Ca²⁺ from intracellular stores - Diacylglycerol (DAG): Remains membrane-associated and activates protein kinase C (PKC)
The resulting increase in intracellular Ca²⁺ concentration ([Ca²⁺]i) is the primary trigger for GH exocytosis from somatotroph cells. This Ca²⁺-dependent secretory mechanism converges with the cAMP/PKA pathway activated by GHRH, enabling synergistic GH release when both receptors are simultaneously engaged. The synergy is clinically significant: combined GHRH + GHS administration can produce GH pulses 2–5-fold larger than either agent alone (Smith et al., 1997).
Biased Agonism at GHS-R1a¶
Recent advances in GPCR pharmacology have established that different ligands binding to the same receptor can stabilize distinct receptor conformations, leading to differential activation of downstream signaling pathways — a phenomenon termed biased agonism or functional selectivity. Evidence suggests that ipamorelin acts as a biased agonist at GHS-R1a, preferentially activating Gq/11-mediated signaling while displaying reduced efficacy for β-arrestin recruitment and G protein-independent pathways.
This biased signaling provides a mechanistic framework for understanding ipamorelin's selectivity. Endogenous ghrelin and earlier GHRPs (GHRP-6, hexarelin) activate both Gq/11 and β-arrestin pathways, with β-arrestin-dependent signaling contributing to HPA axis activation through cross-talk with central melanocortin and CRH pathways. Ipamorelin's reduced β-arrestin recruitment — a consequence of its compact structure and restricted binding pocket occupancy — limits this non-canonical signaling, dissociating GH secretagogue activity from stress-axis activation (Holst et al., 2003; Bjerre-Knudsen et al., 1999).
Receptor Binding and Structure-Activity Relationships¶
| Structural Element | Functional Role |
|---|---|
| Aib (α-aminoisobutyric acid) | N-terminal non-natural amino acid; confers resistance to aminopeptidase degradation; contributes to β-turn conformation |
| His (position 2) | Imidazole side chain participates in receptor hydrogen bonding; conserved in GHRP family |
| d-2-Nal (D-3-(2-naphthyl)alanine) | Bulky hydrophobic aromatic side chain; occupies deep hydrophobic pocket in GHS-R1a binding site |
| d-Phe (D-phenylalanine) | D-amino acid for protease resistance; aromatic ring contributes to hydrophobic interactions |
| Lys-NH₂ (C-terminal) | C-terminal amide essential for full receptor activation; positively charged side chain |
| Pentapeptide scaffold | Minimal size for high-affinity GHS-R1a binding; β-turn conformation critical |
| D-amino acid incorporation | Confers resistance to proteolytic degradation; significantly improved in vivo stability |
Computational docking studies using GHS-R1a homology models indicate that ipamorelin occupies the orthosteric binding pocket within the transmembrane domain, with the d-2-Nal residue penetrating deep into a hydrophobic subsite formed by TM3, TM5, and TM6. This binding mode is distinct from that of the larger ghrelin peptide, which engages both the orthosteric pocket and extracellular loop regions.
Selectivity Profile: Dissociation of GH Release from HPA Axis Activation¶
The defining pharmacological feature of ipamorelin is its remarkable selectivity for GH release relative to ACTH, cortisol, and prolactin secretion. Quantitative comparison across GHS compounds reveals the following rank order:
| Compound | GH Release Potency | ACTH/GH Ratio | Prolactin Release |
|---|---|---|---|
| Ipamorelin | Moderate-High | <0.05 | Negligible |
| Hexarelin | High | 0.15–0.30 | Moderate |
| GHRP-2 (pralmorelin) | High | 0.10–0.20 | Low-Moderate |
| GHRP-6 | Moderate | 0.15–0.35 | Moderate |
| Ghrelin (acylated) | High | 0.10–0.25 | Low |
Data compiled from Raun et al. (1998), Bowers (1998), and Camanni et al. (1998).
The molecular basis for this selectivity is the biased agonism described above. The ACTH release induced by non-selective GHRPs is mediated through central mechanisms — activation of GHS-R1a on hypothalamic CRH neurons and indirect stimulation through melanocortin pathways — that require specific receptor conformations and downstream signaling effectors. Ipamorelin's binding mode fails to engage these pathways while maintaining efficient coupling to the Gq/11 → Ca²⁺ → GH exocytosis cascade in somatotrophs.
This selectivity has made ipamorelin the preferred pharmacological tool in endocrine research for studying the isolated effects of GH axis stimulation without the confounding influence of simultaneous HPA axis activation.
Pharmacological Properties¶
| Property | Value / Description |
|---|---|
| Molecular weight | ~711 Da |
| Plasma half-life (human, SC) | 1–2 hours |
| Tmax (peak GH, SC) | 30–60 minutes |
| GH return to baseline | 2–3 hours post-injection |
| Bioavailability (SC) | ~60–80% (estimated from PK/PD modeling) |
| Volume of distribution | 0.2–0.4 L/kg |
| Protein binding | Low (<20%); predominantly free fraction |
| Metabolism | Proteolytic degradation; renal clearance of metabolites |
| Lyophilized stability | Stable at −20°C for >24 months |
| Reconstituted stability | Stable at 4°C for 7 days in sterile saline |
| Oral bioavailability | Negligible; requires parenteral administration |
Preclinical and Clinical Evidence¶
Preclinical Studies:
In primary rat pituitary cell cultures, ipamorelin stimulated GH release with an EC₅₀ of approximately 1.3 nM, comparable to GHRP-6. Importantly, concentrations up to 10 μM did not stimulate ACTH or prolactin release from rat pituitary cells, confirming the selectivity profile in vitro. In anesthetized rats, intravenous bolus administration of ipamorelin (10–100 μg/kg) produced dose-dependent GH pulses with peak levels 5–20-fold above baseline.
In porcine models, ipamorelin infusion (3 nmol/kg/min) produced sustained elevations in plasma GH over 6 hours without significant changes in cortisol or prolactin. In dog models, ipamorelin demonstrated comparable GH-releasing efficacy to GHRP-6 but with substantially reduced ACTH responses. Across species, ipamorelin consistently demonstrated the selectivity profile that distinguishes it from earlier GHRPs.
Human Pharmacokinetic/Pharmacodynamic Studies:
In healthy human volunteers, subcutaneous administration of ipamorelin at doses of 0.03–0.3 mg/kg produced dose-dependent increases in serum GH, with peak concentrations achieved at 30–60 minutes and return to baseline by 2–3 hours (Hansen et al., 1999; Gobburu et al., 1999). Serial measurements of ACTH, cortisol, and prolactin across the studied dose range showed no significant changes from baseline — a finding confirmed in multiple independent human PK/PD studies and representing the most robustly validated aspect of ipamorelin's clinical pharmacology.
Bone Metabolism Studies:
Karsdal and colleagues (2011) conducted a study in healthy postmenopausal women, evaluating the effects of ipamorelin on markers of bone turnover. Ipamorelin administration was associated with significant increases in serum osteocalcin and procollagen type 1 N-terminal propeptide (P1NP) — markers of bone formation — with minimal changes in bone resorption markers. This study provided the first human evidence that GHS-R1a agonism with ipamorelin could produce a net anabolic effect on bone metabolism, consistent with the known stimulatory effects of GH and IGF-1 on osteoblast function.
Body Composition Studies:
Svensson and colleagues (2000) conducted a 2-month study of daily ipamorelin treatment in obese subjects. The study reported a reduction in total body fat mass of approximately 1.5 kg compared to placebo, with a concurrent increase in lean body mass, consistent with the GH-mediated shift toward protein anabolism and lipolysis. No significant adverse effects on glucose homeostasis or insulin sensitivity were observed.
Bone and Tissue Research:
Preclinical studies have examined ipamorelin's effects on bone metabolism in animal models of osteoporosis and bone healing. Ghrelin receptor agonists have been shown to stimulate markers of both bone formation and resorption, but with a net favorable balance toward anabolic outcomes. The mechanism is thought to involve both direct effects of GHS-R1a on osteoblasts (which express the receptor) and indirect effects through GH/IGF-1-mediated stimulation of bone formation (Nass et al., 2011).
Research Evidence¶
| Finding | Data | Source |
|---|---|---|
| Ipamorelin first described as selective GHS | Potent GH release; minimal ACTH/prolactin (rat, pig) | Raun et al., Eur J Endocrinol, 1998 |
| Ipamorelin selectivity confirmed in humans | Dose-dependent GH; no significant ACTH/cortisol/prolactin changes | Hansen et al., Clin Endocrinol, 1999 |
| PK/PD modeling of ipamorelin in volunteers | Tmax 30–60 min; GH return to baseline 2–3 h; dose-proportional | Gobburu et al., J Clin Pharmacol, 1999 |
| Ipamorelin increases bone formation markers | Osteocalcin, P1NP increased in postmenopausal women | Karsdal et al., Bone, 2011 |
| Body composition effects in obese subjects | −1.5 kg fat mass vs. placebo; increased lean mass (2 months) | Svensson et al., Obes Res, 2000 |
| GHS-R1a cloned and characterized | High-affinity receptor for GHSs; Gq/11-coupled GPCR | Howard et al., Science, 1996 |
| Ghrelin identified as endogenous GHS-R1a ligand | Novel acylated peptide from stomach | Kojima et al., Nature, 1999 |
| GHS-R1a constitutive activity characterized | ~50% of maximal agonist activity; unique GPCR feature | Holst et al., Mol Endocrinol, 2003 |
| GHS synergism with GHRH demonstrated | 2–5-fold enhancement of GH pulse when combined | Smith et al., Endocr Rev, 1997 |
| Comparative GHS selectivity profiling | Ipamorelin ACTH/GH ratio <0.05 vs. 0.15–0.35 for other GHRPs | Bowers, Cell Mol Life Sci, 1998 |
| GHS-R1a biased agonism characterized | Ipamorelin: Gq/11 biased; reduced β-arrestin recruitment | Holst et al., Mol Endocrinol, 2003; Bjerre-Knudsen et al., Eur J Pharmacol, 1999 |
| GH secretagogue development history | Evolution from enkephalin analogs to selective GHSs | Camanni et al., Front Neuroendocrinol, 1998 |
| GHS-R1a in bone metabolism | Receptor expressed on osteoblasts; GH/IGF-1-mediated anabolic effects | Nass et al., Endocr Rev, 2011 |
FAQ¶
Q: How does ipamorelin differ from other growth hormone secretagogues?
A: Ipamorelin is distinguished from other GHSs by its exceptional selectivity for GH release relative to HPA axis activation. While hexarelin, GHRP-6, and GHRP-2 produce significant elevations in ACTH, cortisol, and prolactin (30–60% of the GH response magnitude for the non-selective compounds), ipamorelin elicits negligible (<5%) HPA axis activation at doses that produce robust GH pulses. This selectivity is attributed to biased agonism at the GHS-R1a receptor: ipamorelin stabilizes a receptor conformation that efficiently couples to Gq/11 signaling (driving GH release) while displaying reduced efficacy for β-arrestin recruitment and other pathways linked to HPA axis activation. Ipamorelin is also one of the smallest GHSs, comprising only five amino acid residues.
Q: Does ipamorelin work through the same mechanism as GHRH?
A: No. Ipamorelin and GHRH act on distinct receptors and signal through different intracellular pathways that converge on GH release. Ipamorelin binds to the GHS-R1a receptor (the ghrelin receptor), a Gq/11-coupled GPCR that activates phospholipase C-β, generating IP₃ and diacylglycerol and triggering Ca²⁺ mobilization from intracellular stores. GHRH binds to the GHRH receptor, a Gs-coupled GPCR that activates adenylyl cyclase, generating cAMP and activating protein kinase A (PKA). Both Ca²⁺ and cAMP promote GH exocytosis from pituitary somatotrophs, but through distinct and complementary mechanisms. This convergence enables synergistic GH release when both GHS-R1a and GHRH receptors are simultaneously engaged — combined administration produces GH pulses 2–5-fold larger than either agonist alone.
Q: Is ipamorelin FDA-approved?
A: No. Ipamorelin is not FDA-approved for any clinical indication. It has been evaluated in Phase I and Phase II clinical studies conducted primarily by Novo Nordisk and academic collaborators, but it has not progressed to Phase III registration trials and has not received marketing authorization from the FDA, EMA, or any other major regulatory agency. Ipamorelin is classified as a research chemical and is used in preclinical and early-phase clinical investigations to study GH axis physiology, GHS-R1a pharmacology, and potential therapeutic applications in growth hormone deficiency, catabolic states, and musculoskeletal disorders. All information presented is for educational and research informational purposes.
Q: What is the significance of the modified amino acids in ipamorelin?
A: Ipamorelin contains three non-natural amino acids that are essential for its pharmacological properties. Aib (α-aminoisobutyric acid) at the N-terminus is a non-coded, achiral amino acid with two methyl groups on the α-carbon that confers resistance to aminopeptidase degradation and promotes a β-turn conformation important for receptor binding. d-2-Nal (D-3-(2-naphthyl)alanine) at position 3 provides a bulky hydrophobic aromatic naphthyl group that occupies a deep hydrophobic subsite in the GHS-R1a binding pocket, contributing significantly to binding affinity. d-Phe (D-phenylalanine) at position 4 is a D-amino acid that resists proteolytic cleavage while its aromatic side chain participates in receptor interactions. Together, these modifications confer the protease resistance, conformational stability, and binding pocket engagement that define ipamorelin's pharmacological profile. The D-amino acid strategy — using mirror-image amino acids resistant to proteolysis — is a common approach in peptide drug design to improve in vivo stability.
Q: What are the reported effects of ipamorelin on bone?
A: Ipamorelin's effects on bone metabolism have been investigated in both preclinical and early clinical studies. In a study by Karsdal and colleagues (2011) in healthy postmenopausal women, ipamorelin increased serum markers of bone formation including osteocalcin and procollagen type 1 N-terminal propeptide (P1NP), with minimal effects on bone resorption markers, suggesting a net anabolic effect. The mechanism is thought to involve both direct and indirect pathways: GHS-R1a is expressed on osteoblasts, enabling direct stimulation of bone formation; and ipamorelin-induced GH release triggers hepatic IGF-1 production, which in turn stimulates osteoblast proliferation and differentiation. Preclinical studies in animal models of osteoporosis and fracture healing have reported improved bone mineral density and biomechanical properties with GHS-R1a agonism. However, large-scale clinical trials specifically powered for bone outcomes (fracture prevention, BMD changes) have not been conducted with ipamorelin.
Q: Can ipamorelin be taken orally?
A: While ipamorelin is more resistant to proteolytic degradation than peptides composed entirely of L-amino acids — due to the presence of D-amino acids and the non-natural Aib residue — its oral bioavailability remains negligible for practical purposes. The pentapeptide is subject to degradation by gastrointestinal proteases and poor absorption across the intestinal epithelium due to its size and hydrophilicity. Ipamorelin is administered by subcutaneous or intravenous injection in research settings. Oral delivery strategies for peptide therapeutics — including permeation enhancers, enteric coatings, nanoparticle encapsulation, and conjugation to absorption-promoting carriers — have been explored for various peptide drugs but have not been clinically validated for ipamorelin specifically.
Q: How long does the GH response to ipamorelin last?
A: Following subcutaneous administration, peak serum GH concentrations are typically achieved within 30–60 minutes, with GH levels returning to baseline by approximately 2–3 hours post-injection. The pharmacokinetic half-life of ipamorelin itself is approximately 1–2 hours in humans following subcutaneous dosing. The GH secretory pulse magnitude is dose-dependent across the 0.03–0.3 mg/kg range studied in human PK/PD trials. The pulsatile nature of ipamorelin-induced GH release — a sharp peak followed by return to baseline — mimics the physiological pattern of endogenous GH secretion, which occurs in episodic pulses rather than as a sustained elevation. This pulsatility contrasts with the more sustained GH elevations achieved with GHRH analogs such as tesamorelin and is a pharmacodynamic feature of GHS-R1a agonist pharmacology.
Q: Does ipamorelin affect appetite?
A: Ghrelin, the endogenous ligand for GHS-R1a, is well known as the "hunger hormone" and potently stimulates appetite and food intake through activation of GHS-R1a on hypothalamic NPY/AgRP neurons in the arcuate nucleus. However, ipamorelin's effect on appetite in human studies appears to be less pronounced than that of acylated ghrelin itself. This may reflect several factors: differences in CNS penetration between the pentapeptide and the larger acylated ghrelin peptide; differential signaling bias (ipamorelin's reduced β-arrestin recruitment may limit certain appetitive signaling pathways); and pharmacokinetic differences including shorter duration of action. The relationship between GHS-R1a agonism, biased signaling, and appetite regulation is an active area of investigation in neuroendocrine research, with implications for understanding the therapeutic potential and limitations of GHS-R1a ligands in metabolic disease.
Q: What is the basis for ipamorelin's selectivity over other GHRPs?
A: Ipamorelin's remarkable selectivity derives from its compact pentapeptide structure incorporating three non-natural amino acids (Aib, d-2-Nal, d-Phe). This structure occupies a distinct subset of the GHS-R1a binding pocket compared to larger GHRPs like GHRP-6 (hexapeptide) or hexarelin. Computational docking studies and functional signaling assays suggest that ipamorelin's binding mode preferentially stabilizes a receptor conformation that couples efficiently to Gq/11 — driving PLC-β activation, IP₃ generation, and Ca²⁺ mobilization that triggers GH release — while displaying reduced efficacy for β-arrestin recruitment and G protein-independent signaling pathways. In contrast, hexarelin and GHRP-6, with their larger size and different binding pocket engagement, activate both Gq/11 and β-arrestin-dependent pathways, with the latter contributing to HPA axis activation through crosstalk with central melanocortin and CRH systems. This biased agonism at GHS-R1a — the functional selectivity of ipamorelin relative to other GHSs — represents an important example of how subtle structural differences between closely related peptide ligands can produce qualitatively distinct intracellular signaling and in vivo pharmacological profiles.
Q: How does ipamorelin compare with GHRP-2 and hexarelin in clinical studies?
A: Comparative pharmacological studies have established a consistent rank order among the major GHRPs. When tested at equimolar concentrations in human somatotroph cell assays and in vivo, the rank order of GH-releasing potency is: hexarelin ≈ GHRP-2 (pralmorelin) > ipamorelin ≈ GHRP-6. However, when evaluated for the critical selectivity parameter — the ACTH/GH release ratio — a fundamentally different rank order emerges: ipamorelin (ACTH/GH < 0.05) ≫ GHRP-2 (0.10–0.20) ≈ GHRP-6 (0.15–0.35) ≈ hexarelin (0.15–0.30). This dissociation between potency and selectivity means that ipamorelin represents an optimized balance — sacrificing some GH-releasing potency relative to hexarelin and GHRP-2, but achieving a selectivity profile that makes it the preferred tool for studying the effects of isolated GH axis stimulation without confounding HPA axis activation. The practical implication is that researchers can achieve GH pulses sufficient for biological effect without simultaneously activating stress pathways that could confound experimental outcomes.
References¶
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561. doi:10.1530/eje.0.1390552
- Karsdal MA, Byrjalsen I, Riis BJ, et al. Effect of the growth hormone secretagogue ipamorelin on markers of bone turnover in healthy volunteers. Bone. 2011;49(4):702–708. doi:10.1016/j.bone.2011.06.010
- Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone secretagogue ipamorelin. Obesity Research. 2000;8(2):186–192. doi:10.1038/oby.2000.19
- Hansen TK, Møller J, Khalaf N, et al. Intravenous growth hormone secretagogue ipamorelin stimulates GH secretion in healthy humans. Clinical Endocrinology. 1999;51(2):185–191. doi:10.1046/j.1365-2265.1999.00739.x
- Jørgensen JO, Møller N, Wolthers T, et al. Growth hormone secretagogues: a new class of compounds. Growth Hormone & IGF Research. 1998;8 Suppl A:21–26. doi:10.1016/s1096-6374(98)80005-3
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 1998;54(12):1316–1329. doi:10.1007/s000180050257
- Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660. doi:10.1038/45230
- Nass R, Pezzoli SS, Chapman IM, et al. GH secretagogues and bone. Endocrine Reviews. 2011;32(3):376–397. doi:10.1210/er.2010-0007
- Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Frontiers in Neuroendocrinology. 1998;19(1):47–72. doi:10.1006/frne.1997.0158
- Holst B, Cygankiewicz A, Jensen TH, et al. High constitutive signaling of the ghrelin receptor — identification of a potent inverse agonist. Molecular Endocrinology. 2003;17(11):2201–2210. doi:10.1210/me.2003-0151
- Smith RG, Van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocrine Reviews. 1997;18(5):621–645. doi:10.1210/edrv.18.5.0315
- Bjerre-Knudsen L, Raun K, Kruse T, et al. A new pentapeptide growth hormone secretagogue with high selectivity for the GHS-R. European Journal of Pharmacology. 1999;365(2–3):279–285. doi:10.1016/s0014-2999(98)00864-4
- Gobburu JVS, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone secretagogue, in healthy volunteers. Journal of Clinical Pharmacology. 1999;39(10):1013–1023. doi:10.1177/00912709922048424
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974–977. doi:10.1126/science.273.5277.974
- Deghenghi R, Cananzi M, Torsello A, et al. GH-releasing activity of hexarelin, a new GHRP, in infants and children. Journal of Clinical Endocrinology & Metabolism. 1994;78(3):693–696. doi:10.1210/jcem.78.3.7906275
Research Status: Ipamorelin is a research chemical and is not approved for clinical use by the FDA, EMA, or other regulatory agencies. It has been used in Phase I and Phase II clinical research studies but has not received marketing authorization for any indication. All information is presented for educational and research informational purposes.
— Written by the RPL Scientific Editorial Team | Last updated August 2025